bladder cancer
NICE rejects Keytruda for routine use in NHS bladder cancer treatment
November 27, 2019Research and Development Cancer Drugs Fund, bladder cancer, cancer research
The National Institute for Health and Care Excellence (NICE) has given an initial ‘no’ for Keytruda’s (pembrolizumab) use in treating …
Roche’s Tecentriq meets primary endpoint in Phase 3 bladder cancer trial
August 5, 2019Sales and Marketing Cancer, Roche, bladder cancer, immunotherapy, oncology, tecentriq
Roche has said its immunotherapy drug Tecentriq (Atezolizumab), when used in combination with platinum-based chemotherapy, significantly reduced the risk of …
Scientists use cold virus to treat bladder cancer
July 5, 2019Medical Communications, Research and Development CVA21, Cancer, bladder cancer, oncology, oncolytic, pharma, virus
A strain of the virus that causes the common cold has been found to potentially target, infect and kill cancer …
Janssen’s Balversa becomes first FDA-approved FGFR kinase inhibitor for advanced bladder cancer
April 15, 2019Sales and Marketing Balversa, Cancer, FDA, Janssen, bladder cancer, pharma
Janssen’s Balversa (erdafitinib) has become the first FDA-approved fibroblast growth factor receptor (FGFR) kinase inhibitor after the US agency authorised …
Clovis Oncology discontinue phase 2 bladder cancer trial
April 15, 2019Sales and Marketing Cancer, Clovis Oncology, US, bladder cancer, metastatic bladder cancer
Colorado-based pharma firm Clovis Oncology has said in a filing to the US Securities and Exchange Commission that it is …
17,000 English patients are surviving Stage 4 cancer for two years or more, new data shows
November 8, 2017Research and Development Cancer, bladder cancer, breast cancer, colon cancer, lung cancer, pharma, prostate cancer
At least 17,000 people in the UK are living with Stage 4 cancer and have survived for two years or …
Roche’s Tecentriq scores approvals in metastatic lung and bladder cancer
September 27, 2017Research and Development, Sales and Marketing Cancer, EMA, EU, European Commission, Roche, bladder cancer, immunotherapy, lung cancer, pharma, tecentriq
It’s good news for Roche as the company’s immunotherapy drug Tecentriq secures approval from the European Commission to be used …
Lilly’s Cyramza combo boasts strong results in bladder cancer
September 11, 2017Research and Development, Sales and Marketing Eli Lilly, bladder cancer, cyramza, immunotherapy, pharma
Eli Lilly has announced new Phase 3 data at the European Society for Medical Oncology 2017 Congress which further add …
BMS’ Opdivo scores eighth approval in Europe for bladder cancer
June 5, 2017Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, Europe, European Commission, bladder cancer, immunotherapy
Bristol-Myers Squibb has announced that its flagship immunotherapy treatment Opdivo (nivolumab) has secured its eighth approval in Europe as the …
Potential blockbuster AZ immunotherapy secures FDA approval
May 2, 2017Manufacturing and Production, Sales and Marketing AstraZeneca, bladder cancer, darzalex
The FDA has granted accelerated approval to AstraZeneca’s (AZ) immunotherapy therapy Imfinzi (durvalumab) for the treatment of locally advanced or …
FDA clears Opdivo to treat most common form of bladder cancer
February 6, 2017Sales and Marketing BMS, Bristol-Myers Squibb, MSD, bladder cancer, immunotherapy, keytruda, opdivo
Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …
Roche’s Tecentriq scores another bladder cancer Priority Review
January 9, 2017Sales and Marketing Roche, bladder cancer, tecentriq
Roche has announced that its immunotherapy drug Tecenetriq (atezolizumab) has been awarded Priority Review by the FDA for the treatment …
Bristol-Myers Squibb’s Opdivo gets US FDA breakthrough therapy designation for advanced bladder cancer
June 28, 2016Manufacturing and Production, Research and Development, Sales and Marketing Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, bladder cancer, opdivo, regulation
Bristol-Myers Squibb (NYSE:BMY) said the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to its immunotherapy Opdivo for the …
FDA grants accelerated approval for Roche’s bladder cancer immunotherapy Tecentriq
May 19, 2016Research and Development, Sales and Marketing FDA, Roche, atezolizumab, bladder cancer, immunotherapy, tecentriq
Roche (SIX: RO) has announced that the US Food and Drug Administration (FDA) has granted accelerated approval for Tecentriq (atezolizumab) …
Genentech cancer immunotherapy gets Priority FDA Review in bladder cancer
March 15, 2016Manufacturing and Production, Research and Development FDA, Genentech, Roche, atezolizumab, bladder cancer, priority review
The US FDA has granted Roche subsidiary Genentech a Priority Review for atezolizumab in treating advanced bladder cancer, whose disease …
